The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The Mayo Clinic and Exact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

Novartis said the U.S. Food and Drug Administration has approved the use of Pluvicto against a certain type of prostate cancer. The drug maker said Friday that the FDA green-lit the use of Pluvicto to ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

The FDA has approved Novartis’ Fabhalta (iptacopan) as the first and only treatment for C3 glomerulopathy (C3G). Previously, patients with C3G were forced to rely on supportive care and broad ...